Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women
- PMID: 27183178
- PMCID: PMC4874499
- DOI: 10.1097/QAI.0000000000000928
Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women
Abstract
Background: Recent studies reported that the CD4/CD8 T-cell ratio is inversely associated with biomarkers traditionally used to measure immune activation and systemic inflammation in highly active antiretroviral therapy-treated HIV-infected (HIV+) patients. The relation of hepatitis C virus (HCV) coinfection with the CD4/CD8 ratio in HIV+ patients is unknown.
Methods: We examined 50,201 CD4/CD8 ratios measured over 20 years in 3 groups of HIV+ women enrolled in the Women's Interagency HIV Study: HCV antibody negative (n = 1734), cleared HCV (n = 231), and chronic HCV (n = 751) in multivariate models. IFNL4-ΔG genotype and HCV viral load were also considered.
Results: Compared with HCV antibody negative status, chronic HCV infection was associated with lower CD4/CD8 ratios when HIV viral load was suppressed to the lower limit of quantification (β = -0.08; P = 0.002). Cleared HCV (β = -0.10; P = 0.0009), but not IFNL4-ΔG genotype or HCV viral load, was also associated with lower CD4/CD8 ratios when HIV viral load was suppressed to the lower limit of quantification.
Conclusions: The association of HCV coinfection with CD4/CD8 ratio is consistent with previously observed associations of HCV coinfection with biomarkers traditionally used to measure immune activation and systemic inflammation in HIV+ patients. These data provide additional support for the use of CD4/CD8 ratio for routine monitoring of immune activation and inflammation in HIV+ patients, including those with HIV/HCV coinfection; however, the unexpected association between cleared HCV and lower CD4/CD8 ratio requires additional study.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures



Similar articles
-
Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.AIDS. 2015 Jul 31;29(12):1505-10. doi: 10.1097/QAD.0000000000000650. AIDS. 2015. PMID: 26244390
-
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.J Infect Dis. 2006 May 1;193(9):1202-10. doi: 10.1086/500843. Epub 2006 Mar 17. J Infect Dis. 2006. PMID: 16586355 Free PMC article.
-
Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.J Med Virol. 2016 Aug;88(8):1347-56. doi: 10.1002/jmv.24475. Epub 2016 Jan 20. J Med Virol. 2016. PMID: 26765625
-
Influence of hepatitis C virus coinfection on CD4⁺ T cells of HIV-infected patients receiving HAART.AIDS. 2014 Oct 23;28(16):2381-8. doi: 10.1097/QAD.0000000000000418. AIDS. 2014. PMID: 25111083
-
[Chronic hepatitis C in patients with HIV/HCV coinfection with high CD4+ lymphocytes count].Przegl Epidemiol. 2007;61(3):535-43. Przegl Epidemiol. 2007. PMID: 18069391 Polish.
Cited by
-
Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events.EBioMedicine. 2022 Jun;80:104072. doi: 10.1016/j.ebiom.2022.104072. Epub 2022 May 26. EBioMedicine. 2022. PMID: 35644125 Free PMC article.
-
CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.J Natl Cancer Inst. 2022 Jun 13;114(6):854-862. doi: 10.1093/jnci/djac053. J Natl Cancer Inst. 2022. PMID: 35292820 Free PMC article.
-
Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women.AIDS. 2017 Nov 28;31(18):2483-2492. doi: 10.1097/QAD.0000000000001648. AIDS. 2017. PMID: 29120899 Free PMC article.
-
Neuropsychiatric and laboratory outcomes of hepatitis C treatment in an early-treated HIV cohort in Thailand.AIDS Res Ther. 2025 Feb 19;22(1):20. doi: 10.1186/s12981-025-00707-x. AIDS Res Ther. 2025. PMID: 39972347 Free PMC article.
-
Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study.J Int AIDS Soc. 2019 Jun;22(6):e25297. doi: 10.1002/jia2.25297. J Int AIDS Soc. 2019. PMID: 31250552 Free PMC article. Clinical Trial.
References
-
- Hearps AC, Martin GE, Rajasuriar R, et al. Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep. 2014;11:20–34. - PubMed
-
- Serrano-Villar S, Gutierrez C, Vallejo A, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect. 2013;66:57–66. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R38 AI140299/AI/NIAID NIH HHS/United States
- U01 AI103397/AI/NIAID NIH HHS/United States
- U54 AG062334/AG/NIA NIH HHS/United States
- U01 AI031834/AI/NIAID NIH HHS/United States
- U01 AI035004/AI/NIAID NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- U01 AI103401/AI/NIAID NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- U01 AI103408/AI/NIAID NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- UL1 TR001073/TR/NCATS NIH HHS/United States
- U01 AI103390/AI/NIAID NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- U01 HL146203/HL/NHLBI NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials